- Medicine Name: Vyndaqel
- Generic Name: Tafamidis Meglumine
- Dosage Form & Strength: Capsules: 20 mg
- Manufactured By: Pfizer Inc.
Vyndaqel is a transthyretin stabilizer used for the treatment of the heart disease (cardiomyopathy) of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients to decrease the cardiovascular mortality and cardiovascular-related hospitalization.
Recommended Dosage: The recommended dosage of Vyndaqel is 80 mg (4 × 20 mg tafamidis meglumine capsules) orally once daily. Swallow the capsules whole and not crush or cut. This medicine may be taken with or without food.
If puking occurs after dosing, and the intact Vyndaqel capsule is noticed, then an additional dose of Vyndaqel capsule should be administered if possible. If no capsule is noticed, then no additional dose of Vyndaqel is needed, with resumption of dosing the very next day as usual.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.